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Abstract
Introduction: Preclinical work has suggested that IL-1 plays a critical role in the pathogenesis of rheumatoid
arthritis (RA). The objective of the present study was to determine the effect of a long-acting IL-1 receptor
inhibitor, AMG 108, in a double-blind, placebo-controlled, parallel-dosing study in patients with active RA who
were receiving stable methotrexate (15 to 25 mg/week).
Methods: Patients were randomized equally to receive placebo or 50, 125, or 250 mg AMG 108 subcutaneously
every 4 weeks for 6 months. The primary efficacy endpoint was a 20% improvement in the American College of
Rheumatology response (ACR20) at week 24; other efficacy endpoints included the ACR50, the ACR70, and the RA
disease activity score (28-joint count Disease Activity Score) responses, patient-reported outcomes, and
pharmacokinetic parameters. Safety endpoints included treatment-emergent adverse events (AEs), infectious AEs,
serious AEs, serious infections, injection site reactions, laboratory abnormalities, and antibodies to AMG 108.
Results: Of 813 patients enrolled in the study, 204 patients were randomized to the 50 mg group, 203 to the 125
mg group, 203 to the 250 mg group, and 203 to placebo. At week 24, 40.4% of the 250 mg group, 36% of the 125
mg group, 30.9% of the 50 mg group, and 29.1% of the placebo group achieved an ACR20 (P = 0.022, 250 mg vs.
placebo). Of the individual ACR components, numerical dose-dependent improvements were only seen in tender
joint counts, pain (visual analog scale), and the acute phase reactants, erythrocyte sedimentation rate and C-reactive
protein. No dose-related increase was observed in the incidence of treatment-emergent AEs. No deaths were
reported, and the incidence of AEs and infections, serious AEs and infections, and withdrawals from study for safety
were similar in the AMG 108 and placebo groups.
Conclusions: This large double-blind randomized trial with a long-acting IL-1 receptor blocker, AMG 108, is
consistent with the experience of other IL-1 blockers, represents a definitive experiment showing that IL-1
inhibition provides only moderate symptomatic amelioration of arthritis activity in the majority of RA patients, and
provides an answer to a question that has been discussed for many years in the rheumatologic community.
Trial Registration: ClinicalTrials.gov NCT00293826.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, autoim-
mune, inflammatory arthropathy of unknown etiology,
characterized by progressive destruction of the affected
joints, deformity, disability, and premature death [1].
Genetic and environmental factors have been implicated
in the pathogenesis of RA [2]. The inflammatory
response in the synovial membrane includes hyperplasia,
increased vascularity, and infiltration of inflammatory
cells [3]. Various inflammatory cascades ultimately lead
to activation of macrophages and fibroblast-like synovio-
cytes to overproduce proinflammatory cytokines such as
IL-1, IL-6, and TNFa [4,5]. Other cytokines, as well as
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any medium, provided the original work is properly cited.matrix metalloproteinases, are produced that are respon-
sible for cartilage degradation and bone erosion.
IL-1 is considered a pivotal cytokine in chronic
destructive arthritis; it is a strong activator of chondro-
cytes, induces cartilage breakdown through upregulation
of metalloproteinases, and causes profound suppression
of cartilage matrix synthesis. IL-1 is also able to increase
receptor activator of NF-B ligand expression and thus
drive osteoclast formation and activation [6,7], leading to
bony erosions. Several murine models have shown the
arthritogenic and erosive potency of IL-1. In collagen-
induced arthritis, a frequently used animal model for RA,
TNF was an important contributor to inflammation at
the onset of disease, but IL-1 receptor (IL-1R) blockage
was highly efficacious in reducing inflammation, both in
acute and advanced stages [8]. In antigen-induced arthri-
tis, cartilage damage, erosion progression, and propa-
gation of inflammation are dependent on IL-1 [9,10].
In a recent study of immune complex arthritis, IL-1-
deficient mice were strongly protected [11]. In a novel
transgenic mouse model of adjuvant arthritis, a pure
T-cell model, mice deficient in the IL-1R antagonist dis-
played uncontrolled IL-1 activity and developed sponta-
neous T-cell-dependent autoimmune arthritis [12].
Overall, the preclinical data strongly support a role for
IL-1 in the pathogenesis of synovial inflammation.
In RA patients, however, IL-1 antagonists display rela-
tively modest effects, although they are very effective in
the treatment of systemic-onset juvenile idiopathic
arthritis, of adult-onset Still’s disease, and of several
autoinflammatory disorders [13]. The question remains
whether these inhibitors were given at doses and inter-
vals that would be able to achieve robust coverage of
the IL-1 pathway. We therefore investigated whether
use of more continuous blockade of IL-1 could translate
into increased efficacy in the treatment of RA.
AMG 108 (Amgen Inc., Thousand Oaks, CA, USA) is a
fully human IgG2 monoclonal antibody that binds IL-1R
type 1 and nonselectively inhibits the activity of both
forms of IL-1 (IL-1a and IL-1b). The objective of the pre-
sent study was to compare the efficacy and safety of three
dose levels of AMG 108 with placebo in patients with
active RA who were receiving stable methotrexate
(MTX) (15 to 25 mg/week).
Materials and methods
Patients
Patients were enrolled at 132 study sites in North America
(43% of patients; United States, Canada, Mexico), Eastern
Europe (43% of patients; Poland, Czech Republic, Hun-
gary, Slovakia, Estonia, Latvia), Western Europe (12% of
patients; Netherlands, Spain, Italy, United Kingdom,
F r a n c e ,B e l g i u m ,I r e l a n d ,S w e d e n ) ,a n dA u s t r a l i a( 2 %o f
patients).
Eligible patients were ≥18 and ≤70 years old and had
RA that met the American College of Rheumatology
(ACR) classification criteria [14], with active RA for a
duration ≥6 months. Active RA was defined as ≥6s w o l -
len joints and ≥6 tender or painful joints and at least one
of the following: erythrocyte sedimentation rate (ESR)
≥28 mm/hour, C-reactive protein (CRP) >2.0 mg/dl, or
duration of morning stiffness ≥45 minutes at time of
screening. Patients must have received MTX for at least
12 consecutive weeks, with a stable dose of oral or subcu-
taneous MTX at 15 to 25 mg/week for ≥4 weeks at time
of screening. Exceptions were granted for a lower dose if
it was the highest tolerated dose (toxicity documentation
was required). Patients were allowed to be taking stable
doses of nonsteroidal anti-inflammatory drugs or oral
corticosteroids (≤10 mg prednisone or equivalent) if
doses were stable ≥4 weeks before screening.
Patients were excluded from the study if they had
received any previous AMG 108 or other commercial or
experimental biologic therapies for RA or other inflam-
matory disease, or had uncontrolled or clinically signifi-
cant systemic disease other than RA (for example,
diabetes mellitus, cardiovascular disease, or hyperten-
sion). Patients could not have class IV RA as defined by
ACR revised criteria for global functional status in RA
[15], Felty’s syndrome, a prosthetic joint infection within
5 years or native joint infection within 1 year of screen-
ing, or a major chronic inflammatory disease or connec-
tive tissue disease other than RA (with the exception of
secondary Sjögren’ss y n d r o m e ) .P a t i e n t sc o u l dn o th a v e :
uncontrolled or clinically significant asthma; known sen-
sitivity to mammalian cell-derived drug products; malig-
nancy within 5 years of screening (except for squamous
or basal cell carcinoma or successfully treated in situ
cervical cancer); serious infection (defined as requiring
hospitalization) or recurrent, acute, or chronic infections
within 8 weeks of screening; history of Mycobacterium
tuberculosis or exposure; or known positivity for hepati-
tis B surface antigen, hepatitis C virus, or human immu-
nodeficiency virus.
Patients were ineligible if they had any of the following
clinically significant laboratory values at screening: white
blood cell count <3.0 × 10
9/l, absolute neutrophil count
<2.5 × 10
9/l, platelet count <125 × 10
9/l, aspartate amino-
transferase or alanine aminotransferase >1.5 × upper limit
of normal, serum creatinine >1.5 × upper limit of normal,
or any other laboratory abnormality that, in the opinion of
the investigator, would prevent the patient from complet-
ing the study or would interfere with the interpretation of
the study results. Patients could not have received intra-
articular or systemic corticosteroid injections or any inves-
tigational therapy within 4 weeks of screening, any
disease-modifying antirheumatic drug other than MTX
within 6 weeks of screening, cyclophosphamide within
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of the first dose of investigational product. Patients were
ineligible if, in the investigator’s opinion, they had any
physical or psychiatric disorder that could interfere with
their ability to give informed consent or participate in the
study. Patients with active substance abuse (within
6 months of screening) or any condition that might
require narcotic analgesics were excluded. Pregnant or
nursing women were not eligible, and all sexually active
patients were required to use adequate contraception.
Study design
The investigation was a double-blind, placebo-controlled,
parallel-dosing study in patients with active RA who were
receiving stable doses of MTX (15 to 25 mg/week), were
biologic-naïve, and had discontinued disease-modifying
antirheumatic drugs other than MTX prior to study
entry. Patients were randomized equally to receive pla-
cebo or 50, 125, or 250 mg AMG 108 subcutaneously
every 4 weeks for 6 months.
The study was conducted according to the Declaration
of Helsinki and the International Conference on Harmoni-
sation Tripartite Guideline on Good Clinical Practice [16].
Approvals from appropriate research ethics committees
were obtained from each participating study center (Addi-
tional file 1). All patients provided written informed con-
sent before participating. An external Data Monitoring
Committee monitored patient safety throughout the dura-
tion of the study.
Endpoints
The primary efficacy endpoint was the ACR20 response
[17] at week 24. Secondary efficacy endpoints included
ACR50 and ACR70 responses and the individual compo-
nents of the ACR; the Disease Activity Score using the
28-joint count (DAS28) (using CRP primarily; ESR was
used only if CRP was missing) [18]; and patient-reported
outcomes, including the Disability Index of the Health
Assessment Questionnaire [19], and the physical and
mental composite scores of the Short Form-36 [20] at
week 24. All of these endpoints over time in the study
were analyzed as exploratory endpoints.
Safety endpoints included treatment-emergent adverse
events (AEs), infectious AEs, serious AEs, serious infec-
tions, injection site reactions, laboratory abnormalities,
and anti-AMG 108 antibodies.
The pharmacokinetic profile of AMG 108 in combina-
tion with MTX was also assessed (in 520 patients with
sparse sampling, and in 37 patients with intensive sam-
pling). A validated ELISA was used to quantify AMG 108
in the serum; IL-1R was used as the capture receptor,
and biotinylated IL-1R was used for detection.
Binding antibodies to AMG 108 (anti-drug antibodies)
were evaluated using a validated acid dissociation
electrochemiluminescence-based bridging immunoassay.
Serum samples were collected predose and at weeks 12,
24, and 34. A cell-based bioassay was used to detect
neutralizing antibodies in samples that were positive in
the immunoassay.
Sample size
The primary endpoint was the ACR20 response at week
24. The sample size of 196 patients per treatment arm
was calculated to provide at least 80% power at a statisti-
cal significance level of 5% (two-sided) to test whether
monthly subcutaneous dosing of AMG 108 in combina-
tion with MTX demonstrated an ACR20 response at
week 24 that was >20% above that with MTX therapy
a l o n ei nR As u b j e c t s .T h es a m p l es i z ew a si n f l a t e dt o
allow for a 10% dropout rate over the course of the study.
Statistical analysis
Patients were analyzed according to the randomized
treatment arm regardless of actual treatment received
during the study. All efficacy endpoints were analyzed
using the intent-to-treat analysis set, which included all
randomized patients regardless of whether they received
investigational product. The safety dataset included all
patients who received ≥1 dose of investigational product.
The primary efficacy endpoint compared the ACR20
response rate at week 24 in the 250 mg AMG 108 group
with that of the placebo group. All secondary endpoints
were tested sequentially in a prespecified order to control
the overall family-wise type 1 error rate at 5% (two-sided).
The comparisons of proportions (for dichotomous vari-
ables) among treatment arms were carried out using
Fisher’s exact test. The comparisons of distribution-loca-
tion parameters (for continuous and ordinal variables)
among treatment arms were performed using the Wil-
coxon rank-sum text. For dichotomous variables, missing
values were imputed using a nonresponder imputation
method; for continuous variables, the primary analysis is
based on observed cases.
Results
Patient disposition and disease characteristics
The patient disposition is presented in Figure 1. Rando-
mization was well balanced across groups: 204 patients
were randomized to 50 mg AMG 108, 203 patients to
125 mg AMG 108, 203 patients to 250 mg AMG 108,
and 203 patients to placebo. Of 813 patients enrolled in
the study, 805 (99%) received ≥1 dose of investigational
product. Study completion at week 24 was similar across
treatment groups: 88 to 90% in the AMG 108 groups vs.
93% in the placebo group.
Demographics and baseline disease characteristics are
presented in Table 1. Most patients were women (≥76%
in each group), and most were white (≥83% in each
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groups and was 52.1 years in the placebo group.
Efficacy
In the primary efficacy analysis at week 24 (using the
nonresponder imputation method), the ACR20 response
rate was statistically significantly higher in the 250 mg
AMG 108 group (40.4%) compared with the placebo
group (29.1%; P = 0.022). Small improvements in the
ACR20 response at week 24 were also seen in the 125
mg AMG 108 group (36.0%; Table 2). The ACR20,
ACR50, and ACR70 responses are presented in Table 2.
Only the 250 mg AMG 108 group showed a significant
improvement in ACR50 scores, and no groups were dif-
ferent from placebo with respect to ACR 70.
Additionally, numerical dose-dependent responses were
observed at week 24 in several individual components of
the ACR, including tender joint count, pain (visual analog
scale), ESR, and CRP; all components of the ACR are pre-
sented in Table 3. Responses were weak or absent in swol-
len joint count and physician and patient global
assessments. Median ESR values are shown over time in
Figure 2.
Results of the DAS28 CRP at week 24 are presented in
Table 2. The 125 mg and 250 mg AMG 108 groups had
significantly greater mean improvements from baseline
compared with placebo at week 24 (-0.92 and -1.18,
respectively, vs. -0.60; P < 0.001). Of note, most patients
had moderate disease activity at study entry, as shown
by their baseline DAS28 CRP scores (Table 1). The
European League Against Rheumatism 28-joint count
responses (EULAR28) are also presented in Table 2.
Clinically meaningful improvements were observed in
some patient-reported outcome measures. Mean improve-
ments from baseline at week 24 in the Health Assessment
Questionnaire Disability Index were greater in the 250 mg
and 125 mg AMG 108 groups (-0.40 and -0.34, respec-
tively; P < 0.001, each group compared with placebo) than
in the 50 mg group (-0.24) or the placebo group (-0.19).
Mean improvements from baseline at week 24 in the phy-
sical composite score of the Short Form-36 were numeri-
cally greater in all AMG 108 groups (range 4.6 to 7.2) than
in the placebo group (3.3), and were significantly greater in
the 250 mg group (7.2) compared with placebo (P <
0.001). Improvements in the mental composite score,
however, were similar among the AMG 108 and placebo
groups (data not shown).
Pharmacokinetics
Following single-dose and multiple-dose administration,
AMG 108 is slowly absorbed - with the median time at
which the maximum concentration occurs ranging from
3.8 to 3.9 days (50 mg group), from 3.9 to 4.0 days
(125 mg group), and from 5.9 to 7.0 days (250 mg
 
 
813 patients enrolled 
203 patients 
Placebo 
204 patients 
AMG 108 – 50 mg 
203 patients 
AMG 108 – 125 mg 
203 patients 
AMG 108 – 250 mg 
 15 patients (7%) 
discontinued: 
Protocol deviation:  2 
Noncompliance: 1 
Adverse event: 1 
Withdrew consent: 7 
Alternative therapy: 2 
Lost to follow-up: 1 
Other: 1 
 24 patients (12%) 
discontinued: 
Protocol deviation:  1 
Adverse event: 2 
Withdrew consent: 13 
Alternative therapy: 6 
Lost to follow-up: 2 
 24 patients (12%) 
discontinued: 
Protocol deviation: 3 
Noncompliance: 1 
Adverse event: 3 
Withdrew consent: 11 
Alternative therapy: 3 
Lost to follow-up: 1 
Other: 2 
 21 patients (10%) 
discontinued: 
Protocol deviation: 2 
Noncompliance: 2 
Adverse event: 2 
Withdrew consent: 7 
Alternative therapy: 4 
Lost to follow-up: 2 
Other: 2 
188 patients (93%) 
completed 24 weeks 
180 patients (88%) 
completed 24 weeks 
179 patients (88%) 
completed 24 weeks 
182 patients (90%) 
completed 24 weeks 
Figure 1 Patient disposition. CONSORT diagram.
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AMG 108
Placebo
(n = 203)
50 mg
(n = 204)
125 mg
(n = 203)
250 mg
(n = 203)
Total
(n = 610)
Mean age (years) 52.1 51.4 51.7 52.2 51.8
Age group, n (%)
<65 years 185 (91.1) 171 (83.8) 176 (86.7) 184 (90.6) 531 (87.0)
≥65 years 18 (8.9) 33 (16.2) 27 (13.3) 19 (9.4) 79 (13.0)
Female, n (%) 158 (77.8) 155 (76.0) 163 (80.3) 160 (78.8) 478 (78.4)
Ethnicity, n (%)
White 168 (82.8) 169 (82.8) 177 (87.2) 179 (88.2) 525 (86.1)
Hispanic 27 (13.3) 24 (11.8) 18 (8.9) 17 (8.4) 59 (9.7)
Other
a 8 (3.9) 11 (5.4) 8 (3.9) 7 (3.4) 26 (4.3)
Mean weight (kg) 76.4 77.2 74.2 75.0 75.4
Mean height (cm) 164.0 164.6 164.0 164.8 164.5
Mean body mass index (kg/m
2) 28.4 28.4 27.5 27.5 27.8
Mean duration of RA (years) 7.6 7.3 7.5 8.0 7.6
Subcomponent of ACR (mean)
Tender joint count 26.3 26.5 24.8 26.9 26.1
Swollen joint count 16.8 16.8 15.8 15.7 16.1
Patient global assessment 5.9 6.2 6.1 6.1 6.2
Physician global assessment 6.2 6.3 6.3 6.5 6.4
Patient pain assessment 51.2 53.9 53.5 57.0 54.8
HAQ Disability Index 1.4 1.5 1.5 1.5 1.5
C-reactive protein (mg/dl) 1.2 1.8 1.5 1.4 1.6
ESR (mm/hour) 33.4 40.1 35.6 35.5 37.1
Mean DAS28 CRP 4.7 4.9 4.7 4.8 4.8
Mean DAS28 ESR 5.3 5.4 5.3 5.4 5.3
Mean tender joint count (28 joints) 14.0 14.5 13.5 14.0 14.0
Mean swollen joint count (28 joints) 11.3 10.6 10.8 11.2 11.0
ACR, American College of Rheumatology; DAS28, Disease Activity Score (28-joint count); ESR, erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; RA, rheumatoid arthritis.
aBlack, Asian, American Indian or Alaska native, native Hawaiian or other Pacific Islander.
Table 2 ACR responses, DAS28 C-reactive protein, and EULAR28 responses at week 24
AMG 108
Placebo
(n = 203)
50 mg
(n = 204)
125 mg
(n = 203)
250 mg
(n = 203)
ACR response, n (%)
a
ACR20 59 (29.1) 63 (30.9) (P = 0.746) 73 (36.0) (P = 0.168) 82 (40.4) (P = 0.022)
ACR50 17 (8.4) 24 (11.8) (P = 0.323) 28 (13.8) (P = 0.113) 41 (20.2) (P < 0.001)
ACR70 8 (3.9) 4 (2.0) (P = 0.259) 5 (2.5) (P = 0.575) 12 (5.9) (P = 0.492)
DAS28 CRP, mean change from baseline
b -0.60 -0.69 (P = 0.213) -0.92 (P < 0.001) -1.18 (P < 0.001)
EULAR28 response, n (%)
c
Good 16 (8%) 20 (10%) 28 (13.9%) 39 (19.5%)
Moderate 61 (30.7%) 59 (29.3%) 76 (37.8%) 76 (38%)
No response 122 (61.3%) 122 (60.7%) 97 (48.3%) 85 (42.5%)
ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); EULAR28, European League Against Rheumatism
(28-joint count).
aNonresponder imputation: missing ACR responses were imputed as nonresponder. P values are nominal without multiplicity adjustment, using
Fisher’s exact test.
bObserved cases. P values are comparisons with placebo, using two-sided Wilcoxon rank-sum test.
cEULAR28 response is classified as good,
moderate, and no response based on the DAS28 ESR at week 24 and the DAS28 ESR improvement from baseline at week 24 [31].
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dose group were approximately 10-fold above the pre-
dicted 90% inhibitory concentration for IL-1 (Table 4).
Importantly, trough pharmacokinetic levels were main-
tained in the 125 mg and 250 mg groups, suggesting
prolonged coverage of the IL-1 pathway.
Safety
AMG 108 was well tolerated at all doses administered
during the study. No increase in incidence of treatment-
emergent AEs was observed with increasing AMG 108
dose (Table 5). No deaths were reported, and the inci-
dence of AEs, infectious AEs, serious AEs and infec-
tions, and withdrawals from study due to AEs were no
higher in AMG 108 groups than in the placebo group
(Table 5).
Injection-site reactions occurred more frequently in
AMG 108 groups than in the placebo group (Table 5),
but most reactions were mild or moderate in severity,
with the majority of cases lasting <5 days. Of the 604
patients who received ≥1 dose of AMG 108, 83 patients
(13.7%) were positive for binding antibodies to AMG 108
at some time during the study; 22 patients (4%) were
positive for neutralizing antibodies (data not shown).
No clinically significant changes in laboratory abnorm-
alities were observed, with the exception of expected
decreases in the absolute neutrophil count and platelet
counts that were dose related; these decreases recovered
to baseline values by the end-of-study evaluation (week
34; 10 weeks following the last dose of AMG 108). The
median decreases in neutrophil counts over time are
shown by visit and by treatment group in Figure 3.
Table 3 Improvements in American College of Rheumatology and DAS28 components at week 24
AMG 108
Placebo
(n = 203)
50 mg
(n = 204)
125 mg
(n = 203)
250 mg
(n = 203)
Tender joint count (68 joints)
Mean (SD) % change -20.0 (127.5) -29.5 (60.4) -35.7 (43.6) -40.2 (44.3)
Median % change -31.3 -38.4 -40.0 -46.7
Swollen joint count (66 joints)
Mean (SD) % change -32.2 (50.0) -33.7 (46.5) -33.8 (114.8) -39.1 (53.3)
Median % change -33.1 -40.8 -46.3 -47.1
Patient global assessment
Mean (SD) % change -11.6 (49.8) -16.7 (43.8) -21.6 (48.2) -17.8 (64.5)
Median % change -20.0 -16.7 -28.6 -20.0
Physician global assessment
Mean (SD) % change -30.1 (33.7) -36.0 (30.4) -36.2 (33.2) -43.0 (30.8)
Median % change -33.3 -37.5 -40.0 -50.0
Pain (visual analog scale)
Mean (SD) % change 2.2 (142.6) -11.4 (76.3) -20.6 (60.6) -30.9 (46.9)
Median % change -12.8 -20.0 -28.9 -34.7
HAQ Disability Index
Mean (SD) % change -11.1 (53.0) -12.2 (40.6) -20.5 (48.2) -25.2 (44.6)
Median % change -11.4 -13.3 -20.0 -25.0
Erythrocyte sedimentation rate
Mean (SD) % change 12.7 (77.7) 5 (124.3) -18.3 (68.7) -30.4 (73.7)
Median % change -6.3 -13.2 -36.8 -46.7
C-reactive protein
Mean (SD) % change 123.2 (695.3) 32.2 (164.0) -1.9 (181.5) -25.5 (168.5)
Median % change 5.1 -12.4 -41.2 -59.4
Tender joint count (28 joints)
Mean (SD) % change -13.2 (143.7) -21.0 (73.2) -31.6 (58.7) -36.5 (65.7)
Median % change -33.3 -33.3 -40.0 -44.4
Swollen joint count (28 joints)
Mean (SD) % change -28.2 (52.7) -30.0 (48.1) -28.7 (118.3) -38.0 (52.2)
Median % change -33.3 -33.3 -44.4 -44.4
DAS28, Disease Activity Score (28-joint count); HAQ, health assessment questionnaire; SD, standard deviation.
Cardiel et al. Arthritis Research & Therapy 2010, 12:R192
http://arthritis-research.com/content/12/5/R192
Page 6 of 10Discussion
In the present study of AMG 108 - a long-acting IL-1R
inhibitor - improvements in the signs and symptoms of
RA as measured by the ACR20 were greater in the 250
mg AMG 108 group (40.4%) at week 24, compared with
the placebo group (29.1%; P = 0.022). Improvements in
the ACR50 were also statistically significant for the 250
mg AMG 108 group compared with placebo; however,
the numbers of patients with ACR50 responses were
low (20.2% vs. 8.4%, 250 mg AMG 108 vs. placebo,
respectively; P < 0.001). The ACR70 response was not
significantly different between the two groups. Of note,
mean responses on the Health Assessment Question-
naire Disability Index observed in all groups treated
with AMG 108 were above the minimum clinically
important difference (0.22) published for this outcome
measure [21]. It is interesting that the components of
the ACR responses showing dose-dependent effects in
this study were those that are consistent with the
known functions of IL-1 in pain [22] and in the acute
phase response [23]: AMG 108 decreased pain, tender
joints, ESR, and CRP. The other components of the
ACR scoring system were not affected. AMG 108 was
well tolerated in this patient population, with a safety
profile similar to that of placebo. No dose-related
increases were observed in the incidence of AEs, and no
unanticipated events were reported.
Of interest, the effectiveness of IL-1R blockade with a
long-acting receptor blocker, AMG 108, appears to be
moderate and similar to those described with other IL-1
blockers (such as anakinra, pralnacasan, and IL-1 TRAP)
[24-26], despite a constant concentration of drug esti-
mated to be 10-fold higher than the predicted 90% inhibi-
tory concentration for IL-1. The limited efficacy of IL-1
blockers in RA therefore appears not to be explained
solely by pharmacokinetic or pathway coverage, since the
efficacy provided by AMG 108 was similar to that in other
IL-1 inhibitor studies [27] despite constant inhibition of
the IL-1 pathway for a 6-month period with AMG 108.
The results of treatment with AMG 108 instead appear
to point to a limited role of IL-1 in human RA synovial
inflammation - a notion supported by the profound effect
seen with other IL-1 inhibitors in conditions other than
RA, such as systemic-onset juvenile idiopathic arthritis,
gout, neonatal-onset multisystem inflammatory disease,
cryopyrin-associated periodic syndromes, and other auto-
inflammatory disorders [28,29]. Although it is not known
how many IL-1Rs have to be blocked to prevent IL-1
binding and signaling in a substantial way, AMG 108
achieved steady concentrations in the 250 mg/month
dosing arm that should have been 10-fold higher than
those needed to inhibit 90% of IL-1 signaling. In addition,
dose-dependent changes were seen in those parameters
known to be affected by IL-1, such as pain and acute
Figure 2 Median erythrocyte sedimentation rate over time.
Table 4 Summary of AMG 108 trough concentration (nM) at 20 and 24 weeks
50 mg AMG 108 125 mg AMG 108 250 mg AMG 108
Week 20 (n = 144) Week 24 (n = 137) Week 20 (n = 146) Week 24 (n = 140) Week 20 (n = 137) Week 24 (n = 138)
Mean 0 0 16.5 19.8 155 160
Median 0 0 6.25 4.65 139 141
Range 0 to 6.43 0 to 0.32 0 to 104 0 to 268 0 to 417 0 to 1,000
Below quantifiable levels reported as 0. 90% inhibitory concentration = 13.5 nM, 50% inhibitory concentration = 1.5 nM.
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Page 7 of 10phase reactants. This discrepancy of the IL-1 effect
between the animal models and RA patients may there-
fore be due to differences in timing of treatment, with
animals treated at very early stages of disease and RA
patients at later stages of chronic synovial inflammation,
or may instead be due to differences between the cyto-
kine interactions in rodents versus humans [30].
A limitation of the present study is the absence of radio-
graphic evaluation. The primary analysis was focused on
clinical signs and symptoms rather than on joint damage
measured radiographically; we therefore do not know
whether a more robust benefit than shown in the clinical
findings would have been achieved if radiographs had
been evaluated. Our results may possibly reflect a partial
uncoupling of clinical and radiographic findings.
Conclusions
The present large, double-blind, randomized trial with
a long-acting IL-1R blocker, AMG 108, is consistent
with the experience of other IL-1 blockers, represents a
Table 5 Summary of adverse events through 24 weeks
AMG 108
Placebo
(n = 201)
50 mg
(n = 202)
125 mg
(n = 201)
250 mg
(n = 201)
Total
a
(n = 604)
Any AE 133 (66.2) 134 (66.3) 143 (71.1) 135 (67.2) 412 (68.2)
Most common AE
Headache 16 (8.0) 11 (5.4) 15 (7.5) 15 (7.5) 41 (6.8)
Diarrhea 13 (6.5) 10 (5.0) 11 (5.5) 15 (7.5) 36 (6.0)
Nasopharyngitis 18 (9.0) 11 (5.4) 13 (6.5) 12 (6.0) 36 (6.0)
URI 15 (7.5) 10 (5.0) 13 (6.5) 13 (6.5) 36 (6.0)
Treatment-related AE 48 (23.9) 43 (21.3) 50 (24.9) 45 (22.4) 138 (22.8)
AE leading to:
Study discontinuation 1 (0.5) 3 (1.5) 3 (1.5) 3 (1.5) 9 (1.5)
Withdrawal of study drug 2 (1.0) 4 (2.0) 4 (2.0) 3 (1.5) 11 (1.8)
Hospitalization 9 (4.5) 5 (2.5) 5 (2.5) 6 (3.0) 16 (2.6)
Any infection 72 (35.8) 64 (31.7) 68 (33.8) 62 (30.8) 194 (32.1)
Infection leading to:
Study discontinuation 1 (0.5) 0 0 1 (0.5) 1 (0.2)
Withdrawal of study drug 0 1 (0.5) 0 1 (0.5) 2 (0.3)
Hospitalization 3 (1.5) 1 (0.5) 1 (0.5) 2 (1.0) 4 (0.7)
Injection site reaction 5 (2.5) 8 (4.0) 10 (5.0) 9 (4.5) 27 (4.5)
Any serious AE 11 (5.5) 6 (3.0) 6 (3.0) 9 (4.5) 21 (3.5)
Treatment-related serious AE 2 (1.0) 2 (1.0) 1 (0.5) 1 (0.5) 4 (0.7)
Serious infection 3 (1.5) 2 (1.0) 1 (0.5) 2 (1.0) 5 (0.8)
Death 00000
Data presented as n (%). AE, adverse event; URI, upper respiratory infection.
aAll randomized patients who received at least one dose of AMG 108.
Figure 3 Median neutrophil counts over time by visit and by treatment group.
Cardiel et al. Arthritis Research & Therapy 2010, 12:R192
http://arthritis-research.com/content/12/5/R192
Page 8 of 10definitive experiment showing that IL-1 inhibition pro-
vides only moderate symptomatic amelioration of arthritis
activity in the majority of RA patients, and provides an
answer to a question that has been discussed for many
years in the rheumatologic community - whether use of
more continuous blockade of IL-1 could translate into
increased efficacy in the treatment of RA.
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